Abstract: TH-PO937
Soluble Urokinase Receptor Level as Biomarker in Biopsy-Confirmed Diabetic Nephropathy
Session Information
- Diabetic Kidney Disease: Biomarkers, Pathogenesis
November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 602 Diabetic Kidney Disease: Clinical
Authors
- Lupusoru, Gabriela, Fundeni Clinical Institute, Bucharest, Romania
- Andronesi, Andreea Gabriella, Fundeni Clinical Institute, Bucharest, Romania
- Ailincai, Ioana, Fundeni Clinical Institute, Bucharest, Romania
- Micu, Georgia, Fundeni Clinical Institute, Bucharest, Romania
- Sorohan, Bogdan Marian, Fundeni Clinical Institute, Bucharest, Romania
- Obrisca, Bogdan, Fundeni Clinical Institute, Bucharest, Romania
- Lupusoru, Mircea, UMF Carol Davila Bucharest, Bucharest, Romania
- Fratila, Georgiana, Fundeni Clinical Institute, Bucharest, Romania
- Ion, Oana, Fundeni Clinical Institute, Bucharest, Romania
- Andronesi, Danut, Fundeni Clinical Institute, Bucharest, Romania
- Ismail, Gener, Fundeni Clinical Institute, Bucharest, Romania
Background
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide associated with significant cardiovascular morbidity and mortality. The serum levels of soluble form of podocyte membrane urokinase activator receptor (suPAR) were found to be significantly elevated in patients with DN, making it a potential biomarker for assessing the severity of disease in these patients. The aim of this study was to explore the association between suPAR levels and renal pathological findings in patients with biopsy-confirmed DN.
Methods
We performed a cross-sectional study on 33 patients with biopsy-confirmed DN admitted in our department. The following clinical variables and laboratory parameters were assessed at the time of kidney biopsy: age, gender, time since DM diagnosis, BMI, arterial blood pressure (BP) values, treatment, serum creatinine, estimated glomerular filtration rate (eGFR, calculated by CKD-EPI equation), 24-hour proteinuria and suPAR levels. Histological scoring was made according to that of Tervaert et al (JASN, 2010, 21 (4) 556).
Results
33 patients were included (8 F, 25 M), with mean age 56.6±11.5 y, BMI 28,1±4,3 kg/m2, DM1 (n=4) and DM2 (n=29), months since DM diagnosis (140.7±87.9 mo), hypertensive (n=30), SBP(151.5±24.3mmHg), DBP (83.7±11,1 mmHg), eGFR (34.4± 24.8 ml/min ), serum creatinine (2.74± 1.78mg/dl), 24-hour proteinuria (2.64±2.9g/l), ACEI or ARB use (20/33). Serum suPAR levels were 7.41±3ng/ml. SuPAR levels were positively correlated with age of diabetes (r=0.363, p=0.038), serum creatinine (r=0.493, p=0.004), degree of glomerulosclerosis (r=0.405, p=0.024), degree of tubular atrophy/interstitial fibrosis (r=0.740, p<0.001), degree of arteriosclerosis (r =0.694, p<0.001), and negatively correlated with eGFR (r = -0.675, p<0.001).
Conclusion
Our study confirmed the presence of high serum levels of suPAR in patients with DN and we suggested that these are associated with age of DM, renal function, degree of glomerulosclerosis, tubular atrophy/interstitial fibrosis and arteriosclerosis. Serum suPAR might be a useful biomarker for assessing severity of renal impairment in DN, but requires future validation on larger series of patients